公开(公告)号：US20230416300A1

公开(公告)日：2023-12-28

申请号：US18042103

申请日：2021-08-20

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Peng LI ,  Robert E. DAVIS ,  Yupu QIAO

IPC: C07J43/00

CPC classification number: C07J43/003 ,  C07B2200/05

Abstract: The invention relates to particular substituted (3α,5β-3-hydroxy-pregnan-20-ones, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as sedatives, hypnotics, anxiolytics, and/or anesthetics, and methods for treatment of depression, anxiety, insomnia, epilepsy, and other central nervous system disorders, as well as to combinations with other agents.

公开(公告)号：US20220280517A1

公开(公告)日：2022-09-08

申请号：US17636645

申请日：2020-08-21

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Robert E. DAVIS ,  Peng LI

IPC: A61K31/519 ,  A61P13/12

Abstract: The disclosure relates to methods of administering comprising administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and/or prophylaxis of renal disorders, such as chronic kidney disease. Related compounds and methods of making are further defined.